Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Amarantus Bioscience Holdings (AMBS) Message Board

There is a whole lot of Alzheimer's testing needed

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 30070
Posted On: 08/04/2015 11:10:07 PM
Avatar
Posted By: redspeed
There is a whole lot of Alzheimer's testing needed...

Quote:
Today, at least 50,000 volunteers, both with and without Alzheimer's disease, are urgently needed to participate in more than 130 actively enrolling clinical trials about Alzheimer's and related dementias.



http://www.alz.org/research/clinical_trials/w...trials.asp

Dr. Jeffrey Commings, member of Amarantus's Alzheimer's Disease Diagnostics SAB, is interviewed on Biogen's Aducanumab. The company is currently enrolling patients for an upcoming large scale (2700 participants) 18-month Phase 3 trial.

https://www.youtube.com/watch?v=NVzNBqIevRI

Other trials among the 130 include as example:

Eli Lilly’s solanezumab, is currently running a large phase III trial, slated to end in October 2016, only in people with mild Alzheimer’s disease. Lilly's previous study didn't actually measure amyloid decline.

Axovant anticipates starting a phase 3 trial by the fourth quarter of this year and could bring RVT-101 to pharmacy shelves by as early as 2017

Roche's anti-amyloid plaque monoclonal antibody crenezumab will move into late-stage Phase 3 development. The company is looking to begin new clinical trials of its other monoclonal antibody, ganternerumab, after shutting down a Phase 3 trial in December.


Dr. JEFFREY L. CUMMINGS, M.D., SC.D.
http://www.amarantus.com/about/alzheimers-dis...ostics-sab


(0)
(0)




Amarantus Bioscience Holdings (AMBS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us